Dosing of antipsychotics in schizophrenia across the life-spectrum

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 6, 2009, Pages 917-920

  Uchida, Hiroyuki ^a,b   Mamo, David C ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aging; Antipsychotic; Dopamine; Elderly; Side effect

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR; NEUROLEPTIC AGENT; NORCLOZAPINE; RISPERIDONE; VERAPAMIL;

AGING; CLINICAL TRIAL; DETERIORATION; DISEASE COURSE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SENSITIVITY; EXTRAPYRAMIDAL SYMPTOM; HEALTH SURVEY; HUMAN; METABOLIC DISORDER; MIDDLE AGED; NEUROLOGIC DISEASE; PARKINSONISM; PHARMACODYNAMICS; PRESCRIPTION; RECEPTOR DENSITY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SHORT SURVEY; TACHYPHYLAXIS;

AGE FACTORS; AGING; ANTIPSYCHOTIC AGENTS; HUMANS; LIFE EXPECTANCY; PATIENT COMPLIANCE; SCHIZOPHRENIA;

EID: 67651095785     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.04.023     Document Type: Short Survey

References (44)

1. Alexopoulos G.S., Streim J., Carpenter D., and Docherty J.P. Using antipsychotic agents in older patients. J Clin Psychiatry 65 Suppl 2 (2004) 5-99
2. Antonini A., Leenders K.L., Reist H., Thomann R., Beer H.F., and Locher J. Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride. Arch Neurol 50 (1993) 474-480
3. Ayd Jr. F.J. A survey of drug-induced extrapyramidal reactions. JAMA 25 (1961) 102-108
4. Ballard C., Hanney M.L., Theodoulou M., Douglas S., McShane R., Kossakowski K., et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 8 (2009) 151-157
5. Belitsky R., and McGlashan T.H. The manifestations of schizophrenia in late life: a dearth of data. Schizophr Bull 19 (1993) 683-685
6. Bellodi L., Morabito A., Macciardi F., Gasperini M., Benvenuto M.G., Grassi G., et al. Analytic considerations about distribution of age of onset in schizophrenia. Neuropsychobiology 8 (1982) 93-101
7. Bigos K.L., Pollock B.G., Coley K.C., Miller del D., Marder S.R., Aravagiri M., et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 48 (2008) 157-165
8. Caligiuri M.P., Lacro J.P., and Jeste D.V. Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharmacol 19 (1999) 322-328
9. Carpenter Jr. W.T., and Kirkpatrick B. The heterogeneity of the long-term course of schizophrenia. Schizophr Bull 14 (1988) 645-652
10. Carson S., McDonagh M.S., and Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J Am Geriatr Soc 54 (2006) 354-361
11. Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., and Moller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 6 (2005) 132-191
12. Graff-Guerrero A, Mamo D, Shammi CM, Mizrahi R, Marcon H, Barsoum P, et al. The effect of antipsychotics on the high-affinity state of D2 and the D3 receptors: a Positron Emission Tomography study with [11C]-(+)-PHNO. Arch Gen Psychiatry 2009;66(6):606-15.
13. Harding C.M., Brooks G.W., Ashikaga T., Strauss J.S., and Breier A. The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry 144 (1987) 727-735
14. Howanitz E., Pardo M., Smelson D.A., Engelhart C., Eisenstein N., Stern R.G., et al. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J Clin Psychiatry 60 (1999) 41-44
15. Ichise M., Ballinger J.R., Tanaka F., Moscovitch M., St George-Hyslop P.H., Raphael D., et al. Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT. J Nucl Med 39 (1998) 1511-1518
16. Jabs B.E., Bartsch A.J., and Pfuhlmann B. Susceptibility to neuroleptic-induced parkinsonism-age and increased substantia nigra echogenicity as putative risk factors. Eur Psychiatry 18 (2003) 177-181
17. Jeste D.V., Lacro J.P., Gilbert P.L., Kline J., and Kline N. Treatment of late-life schizophrenia with neuroleptics. Schizophr Bull 19 (1993) 817-830
18. Jeste D.V., Barak Y., Madhusoodanan S., Grossman F., and Gharabawi G. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 11 (2003) 638-647
19. Jeste D.V., Dolder C.R., Nayak G.V., and Salzman C. Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature. Harv Rev Psychiatry 13 (2005) 340-351
20. Kane J.M., Leucht S., Carpenter D., and Docherty J.P. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64 Suppl 12 (2003) 5-19
21. Kennedy J.S., Jeste D., Kaiser C.J., Golshan S., Maguire G.A., Tollefson G., et al. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. Int J Geriatr Psychiatry 18 (2003) 1013-1020
22. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161 (2004) 1-56
23. Lemmens P., Brecher M., and Van Baelen B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 99 (1999) 160-170
24. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50 (2001) 884-897
25. Linden M., Scheel T., and Xaver Eich F. Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study. Hum Psychopharmacol 19 (2004) 111-119
26. Lipkovich I., Baron D., Houston J., Ahl J., and Rotelli M. Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments. J Clin Psychopharmacol 25 (2005) 381-386
27. Loranger A.W. Sex difference in age at onset of schizophrenia. Arch Gen Psychiatry 41 (1984) 157-161
28. Mamo D.C., Sweet R.A., Chengappa K.N., Reddy R.R., and Jeste D.V. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders. Int J Geriatr Psychiatry 17 (2002) 1012-1017
29. Mauri M.C., Volonteri L.S., Colasanti A., Fiorentini A., De Gaspari I.F., and Bareggi S.R. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 46 (2007) 359-388
30. McGlashan T.H. A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 14 (1988) 515-542
31. Ng, W., Uchida, H., Ismail, Z., Mamo, D.C., Rajji, T.K., Remington, G., et al., Clozapine Exposure and the Impact of Smoking and Gender: A Population Pharmacokinetic Study. April 4, 2009 [Electronic-publication ahead of print].
32. Remington G., Seeman P., Shammi C., Mann S., and Kapur S. "Extended" antipsychotic dosing: rationale and pilot data. J Clin Psychopharmacol 25 (2005) 611-613
33. Samaha A.N., Seeman P., Stewart J., Rajabi H., and Kapur S. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27 (2007) 2979-2986
34. Schneider L.S., Dagerman K.S., and Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294 (2005) 1934-1943
35. Seeman P., Bzowej N.H., Guan H.C., Bergeron C., Becker L.E., Reynolds G.P., et al. Human brain dopamine receptors in children and aging adults. Synapse 1 (1987) 399-404
36. Steingard S., Allen M., and Schooler N.R. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse. J Clin Psychiatry 55 (1994) 470-472
37. Taylor D., Paton C., and Kerwin R. The Maudsley 2005-2006 prescribing guidelines. 8th edition (2005), Taylor&Francis, London
38. Toornvliet R., van Berckel B.N., Luurtsema G., Lubberink M., Geldof A.A., Bosch T.M., et al. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 79 (2006) 540-548
39. Uchida H., Mamo D.C., Kapur S., Labelle A., Shammi C., Mannaert E.J., et al. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry 69 (2008) 1281-1286
40. Uchida H., Suzuki T., Mamo D.C., Mulsant B.H., Tanabe A., Inagaki A., et al. Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Am J Geriatr Psychiatry 16 (2008) 584-593
41. Uchida H., Kapur S., Mulsant B.H., Graff-Guerrero A., Pollock B.G., and Mamo D.C. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry 17 (2009) 255-263
42. Uchida H., Mamo D.C., Mulsant B.H., Pollock B.G., and Kapur S. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry 70 (2009) 397-405
43. Wong D.F., Wagner Jr. H.N., Dannals R.F., Links J.M., Frost J.J., Ravert H.T., et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 226 (1984) 1393-1396
44. Wong D.F., Pearlson G.D., Tune L.E., Young L.T., Meltzer C.C., Dannals R.F., et al. Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. J Cereb Blood Flow Metab 17 (1997) 331-342